PUBLISHER: 360iResearch | PRODUCT CODE: 1586292
PUBLISHER: 360iResearch | PRODUCT CODE: 1586292
Chronic Idiopathic Constipation Therapeutic Market by Drug Class (Bulk-Forming Agents, Emollients, Laxatives), Route of Administration (Oral, Parenteral), Distribution Channel - Global Forecast 2025-2030
The Chronic Idiopathic Constipation Therapeutic Market was valued at USD 573.25 million in 2023, expected to reach USD 619.07 million in 2024, and is projected to grow at a CAGR of 8.08%, to USD 987.96 million by 2030.
The Chronic Idiopathic Constipation (CIC) therapeutic market focuses on treatments aimed at relieving prolonged constipation without underlying identifiable causes. This market's scope encompasses a range of pharmaceutical interventions, including laxatives, prokinetic agents, and newer prescription therapies designed to regulate bowel movements and alleviate symptoms. The necessity for CIC therapeutics stems from the significant prevalence of the condition, impacting patient quality of life and burdening healthcare systems. Applications primarily target amelioration of symptoms and prevention of complications, with gastroenterologists and primary care physicians usually spearheading the end-use spectrum through prescription and patient management. Key growth drivers include an aging population more susceptible to chronic constipation and advancements in drug formulations enhancing efficacy and safety profiles. Additionally, increased awareness and diagnosis rates contribute positively to market expansion. However, potential opportunities lie in the development of tailored treatments leveraging biotechnological advances, such as microbiome-modulating therapies or personalized medicine approaches that take into account genetic predispositions. Companies are encouraged to focus R&D efforts on innovative delivery mechanisms and combination therapies to foster patient adherence and improve outcomes. Nevertheless, market growth is constrained by significant challenges, including stringent regulatory frameworks, high research and development costs, and competition from off-label utilization of existing medications. Moreover, the paucity of awareness among physicians regarding newer therapeutic options can limit market penetration. Best innovation areas encompass developing non-systemic therapies with minimized side effects and technologies facilitating real-time monitoring of patient symptoms for more precise treatment adjustments. The CIC therapeutic market is dynamic yet heavily influenced by regulatory policies, competitive pricing, and ongoing clinical trials that shape treatment paradigms. As such, the market landscape necessitates strategic forging of collaborations among drug manufacturers, healthcare providers, and research institutions to accelerate innovative breakthroughs and enhance overall patient care.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 573.25 million |
| Estimated Year [2024] | USD 619.07 million |
| Forecast Year [2030] | USD 987.96 million |
| CAGR (%) | 8.08% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Idiopathic Constipation Therapeutic Market
The Chronic Idiopathic Constipation Therapeutic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Change in lifestyle and dietary
- Higher utilization of OTC drugs by patients
- Rise in healthcare expenditure across the world
- Market Restraints
- Reduced awareness and diagnosis of chronic idiopathic constipation
- Market Opportunities
- Progress in drug delivery mechanisms
- Increase in geriatric population globally
- Market Challenges
- Probable side effects and allergic reactions
Porter's Five Forces: A Strategic Tool for Navigating the Chronic Idiopathic Constipation Therapeutic Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Idiopathic Constipation Therapeutic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Chronic Idiopathic Constipation Therapeutic Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Idiopathic Constipation Therapeutic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Chronic Idiopathic Constipation Therapeutic Market
A detailed market share analysis in the Chronic Idiopathic Constipation Therapeutic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Idiopathic Constipation Therapeutic Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Idiopathic Constipation Therapeutic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Idiopathic Constipation Therapeutic Market
A strategic analysis of the Chronic Idiopathic Constipation Therapeutic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Chronic Idiopathic Constipation Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Albireo Pharma, Inc., Astellas Pharma Inc., Bayer AG, Chugai Pharmaceuticals Co. Ltd., Ferring B.V., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Lantheus Holdings, Mallinckrodt Pharmaceuticals, Pfizer, Inc., Salix Pharmaceuticals, Inc. by Bausch Health, Sanofi S.A., and Takeda Pharmaceutical Company.
Market Segmentation & Coverage
This research report categorizes the Chronic Idiopathic Constipation Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Drug Class, market is studied across Bulk-Forming Agents, Emollients, Laxatives, and Osmotic Agents.
- Based on Route of Administration, market is studied across Oral and Parenteral.
- Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Change in lifestyle and dietary
- 5.1.1.2. Higher utilization of OTC drugs by patients
- 5.1.1.3. Rise in healthcare expenditure across the world
- 5.1.2. Restraints
- 5.1.2.1. Reduced awareness and diagnosis of chronic idiopathic constipation
- 5.1.3. Opportunities
- 5.1.3.1. Progress in drug delivery mechanisms
- 5.1.3.2. Increase in geriatric population globally
- 5.1.4. Challenges
- 5.1.4.1. Probable side effects and allergic reactions
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class
- 6.1. Introduction
- 6.2. Bulk-Forming Agents
- 6.3. Emollients
- 6.4. Laxatives
- 6.5. Osmotic Agents
7. Chronic Idiopathic Constipation Therapeutic Market, by Route of Administration
- 7.1. Introduction
- 7.2. Oral
- 7.3. Parenteral
8. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Hospital Pharmacies
- 8.3. Online Pharmacies
- 8.4. Retail Pharmacies
9. Americas Chronic Idiopathic Constipation Therapeutic Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Chronic Idiopathic Constipation Therapeutic Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Abbvie Inc.
- 2. Albireo Pharma, Inc.
- 3. Astellas Pharma Inc.
- 4. Bayer AG
- 5. Chugai Pharmaceuticals Co. Ltd.
- 6. Ferring B.V.
- 7. GlaxoSmithKline Plc
- 8. Johnson & Johnson Services, Inc.
- 9. Lantheus Holdings
- 10. Mallinckrodt Pharmaceuticals
- 11. Pfizer, Inc.
- 12. Salix Pharmaceuticals, Inc. by Bausch Health
- 13. Sanofi S.A.
- 14. Takeda Pharmaceutical Company
LIST OF FIGURES
- FIGURE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET RESEARCH PROCESS
- FIGURE 2. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 13. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 15. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 21. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET DYNAMICS
- TABLE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING AGENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY EMOLLIENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 20. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 21. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 23. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 24. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 25. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 26. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 27. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 28. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 29. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 30. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 31. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 32. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 33. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 34. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 35. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 36. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 37. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 38. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 39. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 40. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 41. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 42. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 43. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 44. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 45. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 46. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 47. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 48. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 49. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 50. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 51. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 52. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 53. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 54. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 55. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 56. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 57. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 58. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 59. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 60. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 61. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 62. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 63. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 64. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 65. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 66. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 67. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 68. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 69. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 70. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 71. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 72. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 73. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 74. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 75. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 76. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 77. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 78. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 79. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 83. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 84. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 85. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 86. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 87. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 88. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 89. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 90. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 91. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 92. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 93. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 94. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 95. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 96. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 97. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 98. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 99. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 100. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 101. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 102. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 103. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 104. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 105. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 106. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 107. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 108. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 109. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 110. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 111. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 112. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 113. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 114. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 115. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 116. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 117. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 118. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 119. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 120. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 121. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 122. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 123. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 124. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 125. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 126. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 127. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 128. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 129. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 130. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 131. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 132. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 133. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 134. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 135. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 136. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 137. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 138. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 139. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 140. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 141. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 142. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 143. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 144. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
- TABLE 145. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 146. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 147. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023
